151 related articles for article (PubMed ID: 24675130)
1. Muscle strength, joint range of motion, and gait in children and adolescents with osteogenesis imperfecta.
Brizola E; Staub AL; Félix TM
Pediatr Phys Ther; 2014; 26(2):245-52. PubMed ID: 24675130
[TBL] [Abstract][Full Text] [Related]
2. Osteogenesis imperfecta in childhood: perceived competence in relation to impairment and disability.
Engelbert RH; Gulmans VA; Uiterwaal CS; Helders PJ
Arch Phys Med Rehabil; 2001 Jul; 82(7):943-8. PubMed ID: 11441383
[TBL] [Abstract][Full Text] [Related]
3. Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up.
Engelbert RH; Uiterwaal CS; Gerver WJ; van der Net JJ; Pruijs HE; Helders PJ
Arch Phys Med Rehabil; 2004 May; 85(5):772-8. PubMed ID: 15129402
[TBL] [Abstract][Full Text] [Related]
4. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
5. Gait characteristics and functional assessment of children with type I osteogenesis imperfecta.
Graf A; Hassani S; Krzak J; Caudill A; Flanagan A; Bajorunaite R; Harris G; Smith P
J Orthop Res; 2009 Sep; 27(9):1182-90. PubMed ID: 19242979
[TBL] [Abstract][Full Text] [Related]
6. Osteogenesis imperfecta in childhood: impairment and disability.
Engelbert RH; van der Graaf Y; van Empelen R; Beemer FA; Helders PJ
Pediatrics; 1997 Feb; 99(2):E3. PubMed ID: 9099760
[TBL] [Abstract][Full Text] [Related]
7. Commentary on "muscle strength, joint range of motion, and gait in children and adolescents with osteogenesis imperfecta".
Blow CA; McElroy JJ
Pediatr Phys Ther; 2014; 26(2):252. PubMed ID: 24675131
[No Abstract] [Full Text] [Related]
8. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
9. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
10. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
11. [Role of the bone mineral density investigation through measuring of peripheral dual-energetic x-ray absorption in prevention of fractures in children with osteogenesis imperfecta].
Saganelidze KhZ
Georgian Med News; 2005 Mar; (120):61-4. PubMed ID: 15855703
[TBL] [Abstract][Full Text] [Related]
12. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
13. The functional muscle-bone unit in patients with osteogenesis imperfecta type I.
Veilleux LN; Pouliot-Laforte A; Lemay M; Cheung MS; Glorieux FH; Rauch F
Bone; 2015 Oct; 79():52-7. PubMed ID: 26004918
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life of children and adolescents with osteogenesis imperfecta: a cross-sectional study using PedsQL™.
Vanz AP; van de Sande Lee J; Pinheiro B; Zambrano M; Brizola E; da Rocha NS; Schwartz IVD; de Souza Pires MM; Félix TM
BMC Pediatr; 2018 Mar; 18(1):95. PubMed ID: 29499676
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in children with osteogenesis imperfecta: a large-sample study.
Song Y; Zhao D; Li L; Lv F; Wang O; Jiang Y; Xia W; Xing X; Li M
Osteoporos Int; 2019 Feb; 30(2):461-468. PubMed ID: 30569229
[TBL] [Abstract][Full Text] [Related]
16. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
[TBL] [Abstract][Full Text] [Related]
17. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
18. Functional significance of bone density measurements in children with osteogenesis imperfecta.
Huang RP; Ambrose CG; Sullivan E; Haynes RJ
J Bone Joint Surg Am; 2006 Jun; 88(6):1324-30. PubMed ID: 16757767
[TBL] [Abstract][Full Text] [Related]
19. A fracture risk assessment model of the femur in children with osteogenesis imperfecta (OI) during gait.
Fritz JM; Guan Y; Wang M; Smith PA; Harris GF
Med Eng Phys; 2009 Nov; 31(9):1043-8. PubMed ID: 19683956
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
